Archived content

We no longer publish press releases. See the news pages for up-to-date information from NICE.

13 October 2015

NICE launches initiative to speed up adoption of health technologies

NICE is introducing a new service, the Office for Market Access (OMA), an initiative to work with industry to speed up adoption of new medicines, devices and diagnostics by the NHS.

The landscape for the adoption of new health technologies is changing rapidly. The advent of innovative new schemes, such as the MHRA’s Early Access to Medicines Scheme, that allow conditional and adaptive licensing means that health technology providers are being presented with new challenges. Effective engagement opportunities with key organisations, including NICE, is needed to ensure the industry will develop products with meaningful benefits for patients at a price that is affordable to the NHS.

The OMA will give commercial stakeholders access to a dedicated team at NICE that they can approach for enquiries relating to health technology evaluation. The team will offer tailored support, helping stakeholders to identify the most appropriate journey for their products within NICE. With established relationships with regulators, research organisations, NHS organisations, government departments and healthcare trade associations, the team will also facilitate beneficial interactions with the right people.

Professor Carole Longson, NICE health technology evaluation centre director, said: “Technology continues to transform our ability to predict, diagnose and treat disease. New drugs and technologies – many developed here in the UK with our superb science base – are helping to turn conditions that used to disable or kill people into chronic illnesses.

“NICE can encourage the faster development and delivery of new, effective, innovative and affordable drugs and technologies to patients. As part of this, we are launching an Office for Market Access, OMA. OMA will help to improve the rates at which drugs, devices and diagnostics get picked up and adopted by the NHS.

“It will speed up the adoption of innovative and cost-effective health technologies by helping companies to get the right evidence, develop a better business case and engage with the right people.

“OMA will help to deliver the outcomes of the government’s Accelerated Access Review which is intended to clear a path through the regulatory landscape for technology developers to get effective and innovative technologies to patients faster.”

Further details are available at

About NICE

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.

Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.

Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.

To find out more about what we do, visit our and follow us on Twitter: @NICEComms.

NICE can encourage the faster development and delivery of new, effective, innovative and affordable drugs and technologies to patients.

Professor Carole Longson, NICE health technology evaluation centre director